Torrent Pharma gets an observation from USFDA for Pithampur plant

Torrent Pharmaceuticals announced that the USFDA issued a Form 483 with one procedural observation after inspecting its Pithampur manufacturing facility. The inspection took place from September 16-20. Torrent Pharma will respond within the prescribed timeframe and collaborate closely with the USFDA to address the observation. Shares of Torrent Pharma rose by 2.97% on BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wWrzmD0
via IFTTT